Ge Long Hui·2025-08-05 08:41Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are used to treat benign prostatic hyperplasia (BPH) and prevent urinary system events [1] Company Summary - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., is responsible for the newly approved Finasteride tablets [1] - Finasteride tablets are indicated for reducing the risk of acute urinary retention and the need for surgical procedures such as transurethral resection of the prostate (TURP) and prostatectomy [1] - The medication is designed to shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]